Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS G12/G13
KRAS G12/G13 - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between KRAS mutation status in primary tumors and response to oxaliplatin-based first-line therapy, as measured by post treatment PFS. Of 100 patients, 61 had wildtype KRAS and 39 had mutations in KRAS—including G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients with KRAS-mutated tumors were not significantly more resistant to oxaliplatin-based first-line therapy than patients with wildtype KRAS, as evidenced by a nonsignificant difference in PFS (11.7 and 11.4 months, respectively).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6293
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/77
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Does Not Support
- Drug
- Oxaliplatin
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 19603024
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Oxaliplatin | Resitance or Non-Reponse | false |